Cardiac Dysfunction and Metabolic Inflexibility in a Mouse Model of Diabetes Without Dyslipidemia

Diabetes. 2018 Jun;67(6):1057-1067. doi: 10.2337/db17-1195. Epub 2018 Apr 2.

Abstract

Diabetes is a well-established risk factor for heart disease, leading to impaired cardiac function and a metabolic switch toward fatty acid usage. In this study, we investigated if hyperglycemia/hypoinsulinemia in the absence of dyslipidemia is sufficient to drive these changes and if they can be reversed by restoring euglycemia. Using the βV59M mouse model, in which diabetes can be rapidly induced and reversed, we show that stroke volume and cardiac output were reduced within 2 weeks of diabetes induction. Flux through pyruvate dehydrogenase was decreased, as measured in vivo by hyperpolarized [1-13C]pyruvate MRS. Metabolomics showed accumulation of pyruvate, lactate, alanine, tricarboxyclic acid cycle metabolites, and branched-chain amino acids. Myristic and palmitoleic acid were decreased. Proteomics revealed proteins involved in fatty acid metabolism were increased, whereas those involved in glucose metabolism decreased. Western blotting showed enhanced pyruvate dehydrogenase kinase 4 (PDK4) and uncoupling protein 3 (UCP3) expression. Elevated PDK4 and UCP3 and reduced pyruvate usage were present 24 h after diabetes induction. The observed effects were independent of dyslipidemia, as mice showed no evidence of elevated serum triglycerides or lipid accumulation in peripheral organs (including the heart). The effects of diabetes were reversible, as glibenclamide therapy restored euglycemia, cardiac metabolism and function, and PDK4/UCP3 levels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Animals
  • Cardiac Output / drug effects
  • Diabetic Cardiomyopathies / complications
  • Diabetic Cardiomyopathies / drug therapy
  • Diabetic Cardiomyopathies / metabolism*
  • Diabetic Cardiomyopathies / physiopathology
  • Disease Models, Animal*
  • Dyslipidemias / blood
  • Dyslipidemias / complications
  • Dyslipidemias / metabolism
  • Energy Metabolism* / drug effects
  • Gene Expression Profiling
  • Gene Expression Regulation* / drug effects
  • Heart / diagnostic imaging
  • Heart / drug effects
  • Heart / physiopathology*
  • Hypoglycemic Agents / therapeutic use
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / metabolism
  • Metabolomics / methods
  • Mice, Mutant Strains
  • Mice, Transgenic
  • Mutation
  • Myocardium / enzymology
  • Myocardium / metabolism*
  • Organ Specificity
  • Potassium Channels, Inwardly Rectifying / genetics
  • Potassium Channels, Inwardly Rectifying / metabolism
  • Proteomics / methods
  • Stroke Volume / drug effects
  • Ventricular Dysfunction, Left / complications
  • Ventricular Dysfunction, Left / drug therapy
  • Ventricular Dysfunction, Left / metabolism*
  • Ventricular Dysfunction, Left / physiopathology

Substances

  • Hypoglycemic Agents
  • Kir6.2 channel
  • Potassium Channels, Inwardly Rectifying